Bristol-Myers Hangs Tough on ImClone, Despite Icahn’s Mystery Buyer

Jim Cornelius, CEO of Bristol-Myers Squibb, stands behind the company's $60-a-share offer for ImClone Systems in a letter to financier Carl Icahn. The letter doesn't rule out a higher bid, but it casts doubt on the "highly conditional preliminary proposal" from an unnamed potential acquirer.